Analyst Price Targets — KOD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 22, 2026 11:07 am | Matthew Caufield | H.C. Wainwright | $38.00 | $26.71 | TheFly | Kodiak Sciences price target raised to $38 from $26 at H.C. Wainwright |
| January 7, 2026 5:44 am | Michael Yee | UBS | $50.00 | $25.05 | StreetInsider | UBS Starts Kodiak Sciences Inc. (KOD) at Buy |
| September 25, 2025 8:34 am | Gena Wang | Barclays | $17.00 | $15.49 | TheFly | Kodiak Sciences upgraded to Equal Weight from Underweight at Barclays |
| December 9, 2024 11:09 am | Michael Yee | Jefferies | $20.00 | $11.48 | StreetInsider | Jefferies Upgrades Kodiak Sciences Inc. (KOD) to Buy |
| September 24, 2024 10:04 am | Andrea Tan | Goldman Sachs | $2.00 | $2.43 | StreetInsider | Goldman Sachs Reiterates Sell Rating on Kodiak Sciences Inc. (KOD) |
| November 14, 2022 8:46 am | — | Morgan Stanley | $9.00 | $7.59 | Benzinga | Morgan Stanley Maintains Equal-Weight on Kodiak Sciences, Lowers Price Target to $9 |
| November 10, 2022 10:05 am | — | Goldman Sachs | $8.00 | $7.22 | Benzinga | Goldman Sachs Maintains Neutral on Kodiak Sciences, Lowers Price Target to $8 |
| August 15, 2022 8:33 am | — | Morgan Stanley | $12.00 | $11.73 | Benzinga | Morgan Stanley Maintains Equal-Weight on Kodiak Sciences, Raises Price Target to $12 |
| August 10, 2022 9:34 am | — | Chardan Capital | $18.00 | $11.84 | Benzinga | Chardan Capital Maintains Buy on Kodiak Sciences, Lowers Price Target to $18 |
| August 9, 2022 10:22 am | — | Truist Financial | $15.00 | $11.13 | Benzinga | Truist Securities Maintains Buy on Kodiak Sciences, Raises Price Target to $15 |
Latest News for KOD
This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology.
Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company.
Baker Bros. Advisors increased its Kodiak Sciences stake by 2,608,696 shares; the estimated trade size was $53.42 million.
Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report)'s stock price dropped 5.9% on Friday. The stock traded as low as $25.32 and last traded at $25.1010. Approximately 60,109 shares changed hands during trading, a decline of 92% from the average daily volume of 725,091 shares. The stock had previously closed at $26.67. Analyst Upgrades
Connecticut-based Braidwell bought 2,072,788 shares in Kodiak Sciences in the fourth quarter. The quarter-end position value increased by $57.96 million, reflecting the establishment of the new position.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KOD.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.